NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced that the first patient in a Phase 1 clinical study titled, “Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide” has been treated at The University of Kansas Cancer Center (KU Cancer Center).

Many patients with hematological malignancies require a bone marrow transplant for potentially curative treatment. These patients experience a prolonged period of immune deficiency during which time the cancer can return. A matched sibling donor is optimal but only 25% of patients have this option. It takes about three months to obtain the unrelated donor graft, and only half of those patients with an available donor can ultimately receive a transplant due to disease progression.

A partially matched family member (haploidentical) is a viable alternative, but efforts to replace the immune cells can result in severe graft-versus-host disease (GvHD) in which the donor T cells can attack the patient resulting in a significant, even potentially fatal complication. T cells have been shown to be key both in the response to leukemia and in GvHD. About half of all patients who receive a haploidentical transplant will relapse. Incysus Therapeutics has developed this novel γδ T cell approach to allow haploidentical transplantation while providing immune protection to prevent leukemic relapse and infections during the period in which the patient recovers.

Without recognizing traditional “foreign” antigens expressed by the mismatched host, γδ T cells are thought to be able to be delivered from a donor to a patient without generating GvHD. Additionally, γδ T cells, are part of the innate immune system with the ability to recognize and kill cancer cells even after MHC antigen loss, a common driver of leukemic relapse. γδ T cells can also provide a first-line defense against opportunistic viral infections. Further information about this clinical trial (NCT03533816) is available from the National Institutes of Health and can be found here.

“This is the first clinical study to test the innate anti-tumor effect of γδ T cells and the safety of a large bolus of expanded and activated γδ T cells including the risk of GvHD in the allogeneic transplant setting,” commented William Ho, co-founder and Chief Executive Officer of Incysus. “I am pleased that our team has successfully initiated patient enrollment in a second Phase I study. It’s an exciting time for adoptive cellular therapies with a number of companies seeking to develop allogeneic products. With this trial, we hope to bring improved patient outcomes to patients undergoing allogeneic stem cell transplantation and to demonstrate the safety of γδ T cells in the allogeneic setting.” 

Joseph McGuirk, DO, the Division Director, Hematologic Malignancies and Cellular Therapeutics at KU Cancer Center and the study’s principal investigator commented, “Developments in potentially curative stem cell transplants using family donors who have only partially matched immune systems - called haploidentical transplants - have greatly expanded access to stem cell transplantation. This is particularly important for certain ethnic groups, including African Americans, Native Americans and Latinos, who are less likely to have a well-matched family member or matched donor in the worldwide donor registries. However, relapse of the blood cancer for which the patient received the transplant occurs in half of the patients undergoing this procedure. The infusion of donor-derived γδ T cells from the stem cell donor, after being stimulated and expanded in the laboratory, offers the hope of diminishing this risk of relapse and curing more patients.”

About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. The Company’s first clinical program is targeted to leukemia and lymphoma and its second program is targeted for the treatment of newly diagnosed glioblastoma (GBM). Information about the Company’s clinical trial in GBM (NCT04165941) can be found here: http://bit.ly/2Xx5MN6 and for leukemia and lymphoma (NCT03533816) can be found here: http://bit.ly/2pyYFHq. For more information about the Company and its programs, visit www.incysus.com.

About The University of Kansas Cancer Center
The University of Kansas Cancer Center is transforming cancer research and clinical care by linking an innovative approach to drug discovery, delivery and development to a nationally accredited patient care program. Our consortium center includes cancer research and health care professionals associated with the University of Kansas Medical Center and The University of Kansas Health System; the University of Kansas, Lawrence; The Stowers Institute for Medical Research; Children's Mercy; and in partnership with members of the Masonic Cancer Alliance.

Forward Looking Statements
Certain statements herein concerning the Company’s future expectations, plans and prospects, including without limitation, the Company’s current expectations regarding its business strategy, product candidates, and clinical development process and timing, constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Company’s reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.

Contact:
Incysus Therapeutics, Inc.
William Ho, President & CEO
who@incysus.com
+1 646.600.6GDT

info@incysus.com
www.incysus.com